UNION therapeutics announces presentation of new data on orismilast at the 31st EADV Congress
Oral presentation of new preclinical data on pharmacological properties of orismilast at the EADV Congress Additional e-poster details the safety and efficacy of orismilast IR (immediate release) tablets in adults […]
UNION therapeutics completes patient enrollment in the IASOS Phase 2b study of orismilast MR tablet in patients with psoriasis
Topline results expected in first half of 2023 Orismilast is a potent next generation PDE4 inhibitor with broad anti-inflammatory properties also in development for the treatment of hidradenitis suppurativa (HS) […]
UNION therapeutics announces enrollment of the first patient in ADESOS Phase 2b study of orismilast MR tablet in patients with atopic dermatitis
ADESOS is a Phase 2b dose-finding study of orismilast modified release (MR) tablet in moderate to severe atopic dermatitis (AD) with the purpose of identifying the appropriate dose-regimen for Phase […]
UNION therapeutics announces expansion to India of the PROTECT-V Phase 2/3 study of niclosamide nasal spray as COVID-19 prophylaxis
The PROTECT-V Phase 2/3 platform study investigating niclosamide nasal spray as prophylactic treatment for COVID-19 in kidney patients will now be conducted in both the UK and India UK investigators […]
UNION therapeutics announces full year results for 2021 with significant advancement of the clinical pipeline, expansion of international collaborations and strengthening of the organization
Hellerup, Denmark, 17 March 2022 – UNION therapeutics A/S (“UNION”), a privately held, multi-asset, clinical stage, pharmaceutical development company focused on immunology and infectious diseases, announces the full year results […]
UNION therapeutics announces enrollment of first patient in the IASOS Phase 2b study of oral orismilast in psoriasis patients
IASOS is a Phase 2b dose-ranging study of oral orismilast in psoriasis patients with the purpose of identifying the appropriate dose-regimen for Phase 3 studies Orismilast is a next generation […]
UNION therapeutics receives FDA Fast Track designation for oral orismilast for the treatment of moderate to severe atopic dermatitis
FDA’s Fast Track designation for oral orismilast underscores the urgent need for new treatment option with potential to fulfil the unmet medical needs for people affected by atopic dermatitis (AD) […]
UNION therapeutics announces enrollment of first patient in the OSIRIS Phase 2a study of oral orismilast for the treatment of mild to severe hidradenitis suppurativa
OSIRIS is an investigator-led, proof-of-concept Phase 2 study of orismilast for the treatment of mild to severe hidradenitis suppurativa (HS) HS is a scarring inflammatory skin disease with significant unmet […]
UNION therapeutics and Innovent Biologics enter into strategic collaboration and license agreement for orismilast, a next-generation PDE4 inhibitor for inflammatory dermatology conditions
Orismilast is a potential best-in-class PDE4 inhibitor in Phase 2 clinical development for the treatment of atopic dermatitis, psoriasis, and hidradenitis suppurativa Innovent will be granted exclusive rights to research, […]
UNION therapeutics welcomes life science leaders Gitte Aabo and Arthur Higgins as new members of the Board of Directors
Hellerup, Denmark, 12 July 2021 – UNION therapeutics A/S, a privately-held, multi-asset, clinical stage pharmaceutical company focused on immunology and infectious diseases, today announced that Gitte Aabo, CEO of GN […]